Asahi shares mark weekly slide after cyberattack halts production
LONDON - Redx Pharma will present new Phase 2a clinical trial data for its idiopathic pulmonary fibrosis (IPF) drug candidate zelasudil at the upcoming European Respiratory Society (ERS) meeting in Amsterdam, according to a company statement released Monday.
Professor Toby Maher, the study’s Chief Investigator and Director of the Interstitial Lung Disease Programme at Keck School of Medicine, University of Southern California, will deliver the oral presentation on Sunday, September 28.
The presentation, titled "Phase 2a signal searching study with zelasudil in idiopathic pulmonary fibrosis (IPF)," will share findings from trials evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of zelasudil in IPF patients.
Zelasudil is described as a potent, oral, small molecule that selectively inhibits Rho Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2).
IPF is a progressive lung disease characterized by scarring and reduced lung function, primarily affecting adults over 50 years of age. The condition leads to shortness of breath and impaired oxygen absorption. According to information provided in the press release, over 170,000 patients suffer from IPF across the US, five European countries, and Japan, with approximately 53,000 new diagnoses annually. The disease has an estimated life expectancy of 3 to 5 years after diagnosis, with current treatments only slowing disease progression.
The ERS meeting will take place at RAI Amsterdam from September 27 to October 1, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.